Sugi Predict

Sugi Predict / Compounds / SCHEMBL142572

SCHEMBL142572

SCHEMBL142572

CC(C)Cn1c(=O)[nH]c2c(N)nc3ccccc3c21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 9/20 0.53
▸ LMNA P02545 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ HRH2 P25021 1/20 0.51
▸ ADRA1D P25100 1/20 0.51
▸ HTR2A P28223 1/20 0.51
▸ ADORA2A P29274 1/20 0.51
▸ ADRA1A P35348 1/20 0.51
▸ NUDT1 P36639 1/20 0.51
▸ HTR2B P41595 1/20 0.51
▸ PDE4D Q08499 1/20 0.51
▸ KCNH2 Q12809 1/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ TLR8 Q9NR97 1/20 0.46
▸ NPC1 O15118 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31092874 1.00 TLR7 (0.53) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL12296513 0.80 SMN1; SMN2 (0.44) TLR7LMNAADORA2ASMN1; SMN2ALDH1A1
SCHEMBL3274293 0.80 TLR7 (0.42) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL1046834 0.77 L3MBTL1 (0.39) TLR7ALDH1A1TLR8L3MBTL1
SCHEMBL24732897 0.76 TLR7 (0.52) TLR7NUDT1TLR8MEN1KMT2A
SCHEMBL24732710 0.75 TLR7 (0.56) TLR7
SCHEMBL24732756 0.75 TLR7 (0.56) TLR7ALDH1A1TLR8CYP1A2CYP2D6
SCHEMBL24732573 0.75 TLR7 (0.47) TLR7ADORA2ASMN1; SMN2ALDH1A1CYP1A2
SCHEMBL29809462 0.75 TLR7 (0.56) TLR7ALDH1A1TLR8CYP1A2CYP2D6
SCHEMBL29809167 0.75 TLR7 (0.47) TLR7ADORA2ASMN1; SMN2ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096103-A1 IMIDAZOQUINOLINE COMPOUNDS NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2013-04-18 — — US claimed
US-20110217323-A1 IMIDAZOQUINOLINE COMPOUNDS NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2011-09-08 — — US claimed
CN-101056877-B Imidazoquinoline compounds NOVARTIS VACCINES & DIAGNOSTIC 2010-06-09 — — CN claimed
US-20080213308-A1 Imidazoquinoline Compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-09-04 — — US claimed
EP-4585610-A2 MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS Seqirus UK Limited (GB) 2025-07-16 — — EP disclosed
EP-4144368-B1 RSV IMMUNIZATION REGIMEN GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-02-26 — — EP disclosed
EP-3527224-B1 RSV IMMUNIZATION REGIMEN GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-02-26 — — EP disclosed
US-20250042951-A1 PRE-FUSION RSV F ANTIGENS NOVARTIS AG (CH) 2025-02-06 — — US disclosed
CN-114269749-B 5H-pyrrolo [3,2-d ] pyrimidine-2, 4-diamino compounds and antibody conjugates thereof 苏特罗生物制药公司 2024-10-01 — — CN disclosed
US-20240299527-A1 RSV IMMUNIZATION REGIMEN NOVARTIS AG (CH) 2024-09-12 — — US disclosed
US-20240299537-A1 ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE SEQIRUS UK LTD (GB) 2024-09-12 — — US disclosed
US-20240239845-A1 PRE-FUSION RSV F ANTIGENS NOVARTIS AG (CH) 2024-07-18 — — US disclosed
US-20080213308-A1 Imidazoquinoline Compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-09-04 — — US disclosed
US-20080213308-A1 Imidazoquinoline Compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-09-04 — — US disclosed
US-20080213308-A1 Imidazoquinoline Compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-09-04 — — US disclosed
US-20080193470-A1 For immunizing against MNEC infections GLAXOSMITHKLINE VACCINES S.R.L. (BE) 2008-08-14 — — US disclosed
CN-101203529-A Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli NOVARTIS VACCINES & DIAGNOSTIC (US) 2008-06-18 — — CN disclosed
CN-101180312-A Immunogens from uropathogenic escherichia coli NOVARTIS VACCINES & DIAGNOSTIC (US) 2008-05-14 — — CN disclosed
WO-2007126825-A2 COMBINED MUCOSAL AND PARENTERAL IMMUNIZATION AGAINST HIV NOVARTIS AG (CH) 2007-11-08 — — WO disclosed
CN-101056877-A Imidazoquinoline compounds NOVARTIS VACCINES & DIAGNOSTIC (US) 2007-10-17 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042951-A1 PRE-FUSION RSV F ANTIGENS FURIN, CD69, LY96 TLR7 485/4885LMNA 480/4885POLB 3894/4885
US-20130096103-A1 IMIDAZOQUINOLINE COMPOUNDS IFNG, IRF3, MYD88 TLR7 13/4885LMNA 4398/4885POLB 2702/4885
US-20240299527-A1 RSV IMMUNIZATION REGIMEN IL5, IL15, IFNG TLR7 48/4885LMNA 4368/4885POLB 1481/4885
US-20110217323-A1 IMIDAZOQUINOLINE COMPOUNDS IFNG, IRF3, MYD88 TLR7 13/4885LMNA 4398/4885POLB 2702/4885
US-20240239845-A1 PRE-FUSION RSV F ANTIGENS FURIN, CD69, LY96 TLR7 485/4885LMNA 480/4885POLB 3894/4885
US-20080193470-A1 For immunizing against MNEC infections MLEC, GMFG, MYD88 TLR7 343/4885LMNA 2127/4885POLB 1993/4885
US-20240299537-A1 ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE LY96, PHOSPHO1, ASGR1 TLR7 73/4885LMNA 2986/4885POLB 1062/4885
US-20080213308-A1 Imidazoquinoline Compounds IFNG, IRF3, MYD88 TLR7 13/4885LMNA 4398/4885POLB 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.